<div id="readability-page-1"><div><p>Health-care companies rose after one potential breakthrough on a brain disease.</p><p>    Bristol Myers Squibb rallied after the biopharmaceutical company said that it was adding patients for its study on its drug, Cobenfy, to treat psychosis in patients with Alzheimer's disease. </p><p>    Shares of Eisai, which produces Alzheimer's treatment Leqembi in collaboration with Biogen, fell slightly. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-03-25 1736ET</p></div></div>

百时美施贵宝

<p>医疗保健公司在一项针对脑部疾病的潜在突破后上涨。百时美施贵宝在生物制药公司表示将增加其针对阿尔茨海默病患者精神病治疗药物 Cobenfy 的研究患者后，股价上涨。与 Biogen 合作生产阿尔茨海默病治疗药物 Leqembi 的 Eisai 股价略微下跌。请联系 Rob Curran，邮箱为 rob.curran@dowjones.com (完) 道琼斯新闻社 12-03-25 1736ET</p>

医疗保健因对阿尔茨海默症的希望而上涨 - 医疗保健综述